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Vitamin D is not a stranger to most health professionals. It is a fat-soluble compound that promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate concentrations to enable normal bone mineralization and metabolism. Vitamin D has many other possible roles. Some of these are well-documented such as the prevention of rickets, a condition related to deficiency of this vitamin. Other less well-proven possible benefits include improving cognitive function, prevention of certain cancers, reducing the risk of multiple sclerosis and treatment of plaque-type psoriasis.[@bib0001]

With the limited space available, this column will condense what could be a multi-volume treatise into some very basic findings and principles that provide at least circumstantial evidence, but backed by considerable scientific data, that vitamin D may potentially play an important role in preventing or ameliorating the multi-system consequences of COVID-19 infections.

The role of vitamin D in COVID-19 is highly speculative as is the case with many potential treatments since the virus is so new to us. But, there is a sound reasoning behind this speculation.

Briefly, and only partially explained in the following text, T regulatory lymphocytes (TRegs) are a principal defense against uncontrolled inflammation. The number of TRegs has been found to be markedly lower in patients with severe COVID-19 infection whereas elevated TReg levels have been found to be associated with a reduced level of respiratory viral disease. TReg level can be increased by vitamin D. In addition, low vitamin D serum concentrations are associated with an increase in inflammatory cytokines which raises the possibility that adequate vitamin D concentration may reduce the incidence of cytokine storm which can occur in COVID-19 infection.[@bib0002] As well, thrombotic complications are common in COVID-19 and vitamin D deficiency is also involved in an increase in thrombotic episodes which raises further speculation about the importance of adequate vitamin D serum concentration.[@bib0002]

Numerous observational studies have reported an association between low serum concentration of 25-hydroxyvitamin D \[25(OH)D\] (the major circulating vitamin D metabolite) and susceptibility to acute respiratory infection. The proposed mechanism of this has been outlined in detail for the interested reader.[@bib0003] These findings led to randomized controlled trials to determine if vitamin D supplementation would reduce risk of acute respiratory infection and results were mixed. This was followed by a 2016 meta-analysis of studies assessing the overall effect of vitamin D supplementation on risk of acute respiratory infection which determined that vitamin D supplementation provided overall protection against acute respiratory infection. It further determined that patients who were very vitamin D deficient experienced the most benefit. Study authors found that daily or weekly vitamin D supplementation without additional bolus doses protected against acute respiratory infection whereas regimens containing large bolus doses of vitamin D did not, so this finding can be used when considering a vitamin D dosing regimen.[@bib0004]

As the ongoing COVID-19 pandemic has spread to all countries and regions, with the exception of Antarctica, epidemiologists have noted that mortality from COVID-19 differs, sometimes significantly, between nations. This difference has been attributed to a variety of factors including the average age of the population. For example, Italy has had a high COVID-19 mortality rate and a large portion its population is over age 65. Other factors possibly affecting COVID-19 mortality rate include differences in socioeconomic status, and accessibility and quality of health care.[@bib0005] Yet, interpretation of death rates based on these factors falls short of providing a complete answer, because, for example, Japan, the nation with the greatest percentage of population over age 65, has a COVID-19 mortality rate which is only a fraction of Italy\'s.

Another factor that is now garnering considerable attention is the vitamin D status of affected populations. When mortality is plotted against latitude it can be seen that countries that lie below 35° north latitude have relatively low mortality. Above this latitude the population does not generally receive sufficient sunlight so they will not be able to retain adequate vitamin D stores and serum concentrations during winter, likely resulting in vitamin-D deficiency. There are exceptions to this such as Norway, Sweden and Finland. Despite the fact that these Nordic nations receive lower levels of sunlight, vitamin D supplementation and fortification of foods is common. On the other hand, Spain and Northern Italy, while at lower latitudes, have high rates of vitamin D deficiency and higher COVID-19 mortality rates.[@bib0006] The authors of this study propose that vitamin D supplementation will reduce serious complications and they point out that in England, Scotland and Wales, public health bodies have revised recommendations since the COVID-19 outbreak and now state that all adults should take at least 400 IU vitamin D daily. They aptly point out that "Whereas there are currently no results from randomized clinical trials to conclusively prove that vitamin D beneficially affects COVID-19 outcomes, there is strong circumstantial evidence of associations between Vitamin D and severity of COVID-19 responses including death." Vitamin D deficiency also correlates with hypertension, diabetes, obesity and ethnicity which are all features associated with increased risk of severe COVID-19.

Consistent with this is a recently published narrative which provides an interesting discussion of the relationship of vitamin D concentrations and its relationship with COVOD-19 infections. They noted that the outbreak occurred in winter, a time when 25(OH)D concentrations are lowest; that the number of cases in the Southern Hemisphere near the end of summer were low; that vitamin D deficiency has been found to contribute to acute respiratory distress syndrome; and that case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 25(OH)D concentration.[@bib0003]

Vitamin D status can be monitored quantitatively through laboratory determination of 25(OH)D. I am not aware of specifically recommended vitamin D serum concentrations to prevent or lessen the impact of COVID-19 that are endorsed by governmental agencies or professional societies but it would seem reasonable to use current recommendations as a reference point although, individual researchers may have different recommendations. The recommendations of the US Institute of Medicine state that a serum concentration between 20 and 50 ng/mL is generally considered adequate for bone and overall health in healthy individuals.[@bib0007]

As I have frequently mentioned in my columns, the most important consideration in regarding drug therapy in older adults, in patients of any age, for that matter, is weighing the potential risks of a therapy compared to potential benefits. When looking at the data and rationale supporting the administration of supplemental vitamin D it is not difficult to perform a quick risk/benefit analysis to conclude that potential benefits far outweigh potential risks.

While there are many ways to prescribe vitamin D supplementation the following regimen is proposed in one detailed review of the Vitamin D and influenza and COVID-19.[@bib0003] "To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/day of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/day. The goal should be to raise 25(OH)D concentrations above 40--60 ng/mL. For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful." The authors further clarify these recommendations by stating, "Randomized controlled trials and large population studies should be conducted to evaluate these recommendations."[@bib0003]

I encourage the readers to keep tuned for more information on dosage regimens and recommended target vitamin 25(OH)D serum concentrations. As more specific vitamin D recommendations will be published there will surely be other therapeutic options that may help to lessen the impact of COVID-19. For example, as I complete this manuscript, the newswires report that the FDA has withdrawn its emergency use authorization allowing use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Also in the news is the pre-publication data of a study that has been reported to have demonstrated the positive effect of dexamethasone administration in reducing COVID-19 mortality. I believe that increasingly, we will be hearing about other such developments until eventually, and it will be sooner rather than later, a preventative vaccine will be widely available.

I maintain the optimism that I expressed in my most recent column two months ago that a vaccine will likely be available in less than a year, and, with the passage of time since my original forecast, that means less than 10 months away. I grow more confident in this prediction as new information on vaccine research is published. There are now more than 100 vaccines in various stages of clinical trials with some scheduled to enter the all-important Phase-3 in July 2020 where thousands of people will be given the vaccines to give a real test of its ability to prevent COVID-19 infection. And, we could be in for some surprises including the possibility of China coming out of left field with the first effective vaccine. This is pure speculation on my part but wouldn\'t it be interesting for that nation, which has been unfairly blamed for creating or somehow enabling this virus, to come up with the preventive vaccine?
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